In @nejm.org, the ASCENT04 trial by @danafarbernews.bsky.social’s @stolaney1.bsky.social shows sacituzumab govitecan plus pembrolizumab as first-line therapy led durable responses and improved progression-free survival for pts w/advanced PD-L1 positive triple negative breast cancer. bit.ly/4qASzj5